Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on Tuesday. Omvoh is now indicated for both forms of inflammatory bowel ...

The approval marks the first Alzheimer's therapy registered in Australia that targets amyloids, helping slow the cognitive and functional decline in patients with early symptoms, the company said.

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use intravenously.

Eli Lilly and Company (NYSE:LLY) recently announced that Australia's Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing.

Photo: mike blake/Reuters Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Biotech Stocks This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly Verve Therapeutics’ stock was soaring toward a record gain on Eli Lilly’s premium ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first amyloid-targeting Alzheimer's therapy. Read more here.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

By Kelly Cloonan Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. The company has also worked hard to diversify its pipeline. The stock is worth the premium. And that's before we get into ...